Reviews/Psoriasis Psoriatic Arthritis/IL-17 inhibitors associated with inflammatory bowel disease incidence
Psa CVD · PSA-CVD-03 · v2
This claim asks whether people taking IL-17 inhibitors for psoriasis or psoriatic arthritis develop new or worsening inflammatory bowel disease more often than people on other advanced therapies. Two large real-world studies found that IBD occurred more often with IL-17 inhibitors than with apremilast [1][2], and safety-reporting databases picked up a matching signal [3][4]. But the picture is not uniform: the same nationwide study found no difference versus the TNF inhibitor etanercept [2], and another adjusted study found no clear difference versus untreated patients [6]. The number of people who actually developed IBD stayed low across all studies, and in one series the rate fell over time [5]. So the direction of the association is well supported against one comparator, but the broad 'versus all other advanced therapies' framing is only partly backed by this evidence.
Two large population-based cohorts report more IBD with IL-17 inhibitors than with apremilast: 142 versus 60 cases and aHR 2.50 (1.85-3.39) in [1], and weighted HR 3.8 (2.1-6.8) in [2]. Pharmacovigilance databases reinforce this direction, with 850 IBD reports in VigiBase [3] and a FAERS secukinumab signal of PRR 4.65 (3.66-5.89) [4], echoed by a further FAERS ulcerative colitis signal [7]. A prospective study also associates IL-17 inhibitors with new-onset and flares of IBD [8]. Against this, [2] found no difference versus etanercept (HR 0.8, 0.5-1.2), and [6] found no significant difference versus unexposed patients (OR 1.37, 0.57-3.33). Absolute incidence was consistently low, including a fall to 0.08/100 patient-years in [5]. The contested point: The evidence divides on the comparator: the increased risk is clear versus apremilast [1][2] but absent versus etanercept [2] and versus unexposed patients [6]. The claim's 'compared to other advanced therapies' wording therefore holds against one drug but not across the class.
All 8 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Psoriasis Psoriatic Arthritis, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The increase is anchored to apremilast, a plausibly IBD-neutral comparator; the same nationwide cohort [2] found NO difference versus etanercept (HR 0.8, 0.5-1.2), so the class-wide claim 'compared to other advanced therapies' is not uniformly supported.
Three of the eight sources [3][4][7] are disproportionality/reporting-ratio analyses with no denominator and susceptibility to notoriety and reporting bias; these establish a reporting signal, not an increased risk.
Where it remains uncertain. The same nationwide cohort found no difference versus etanercept (HR 0.8 [2]) and an adjusted cohort found no difference versus unexposed patients (OR 1.37 [6]), so the class-wide comparison is only partly supported.
Aleatory
IBD is a rare outcome (0.43% of IL-17i users [2]; 0.27% one-year incidence [6]), so estimates rest on few events and carry wide random variation, as the crossing interval in [6] shows.
Epistemic
Only apremilast and etanercept are directly compared [1][2]; other advanced therapies (JAK inhibitors, IL-23, IL-12/23 agents) are absent, so the class-wide comparison is unmeasured.
Inferential
Reports in [3][4][7] have no denominator and are prone to notoriety and reporting bias, so they support a reporting signal, not a quantified increased risk.
The load-bearing papers from a corpus of 8, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Primary comparative evidence of increased IBD risk vs an advanced therapy (apremilast).
“Among 13,216 matched patients per group, 142 developed IBD with IL-17 inhibitors versus 60 with apremilast (aHR = 2.50, 95% CI: 1.85-3.39).”
Panel auditInternal validity: medium · scope of inference: Psoriasis and psoriatic arthritis patients, IL-17 inhibitor versus apremilast, new-onset IBD.Key limitations: single active comparator (apremilast) · residual confounding not characterised in abstract · no indication-specific breakdown
Confirms increase vs apremilast but shows the comparator dependence — null vs a TNF inhibitor.
“the risk of IBD was significantly greater among patients initiating an IL-17i compared to those initiating apremilast (weighted HR 3.8 [95% CI 2.1-6.8]). No difference in IBD risk between new IL-17i users and new etanercept users was observed (weighted HR 0.8 [0.5-1.2]).”
Panel auditInternal validity: medium · scope of inference: Psoriasis, psoriatic arthritis and ankylosing spondylitis patients initiating IL-17 inhibitors, IBD risk versus apremilast and versus etanercept.Key limitations: signal is comparator-dependent (present vs apremilast, absent vs etanercept) · low absolute event rate (0.43%) · confounding by indication possible
Pharmacovigilance signal supporting new-onset and worsening IBD association.
“Treatment with IL-17 inhibitors is associated with a relevant number of exacerbations and new onset of IBD and colitis.”
Panel auditInternal validity: low · scope of inference: Global spontaneous reports of gastrointestinal/IBD events under secukinumab and ixekizumab.Key limitations: no comparator group · no denominator or incidence · reporting and notoriety bias
Although titled case-control, the abstract gives only single-arm incidence figures (0.69 to 0.08/100 patient-years) with no comparator estimate, so the comparative direction is not determinable.
Panel auditInternal validity: low · scope of inference: New-onset IBD incidence and clinical course under IL-17 inhibitors (all cases secukinumab).Key limitations: no comparative estimate reported in abstract · small case count · declining incidence may reflect prescribing/reporting changes
4 of 8 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Reproducible increased-risk signal versus apremilast across independent datasets supports the claim directionally, while the null result versus a TNF inhibitor and low absolute incidence hold it below the Established band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
IL-17i versus non-apremilast advanced therapies. The class-wide comparison rests on apremilast alone; [2] already shows the signal disappears versus etanercept, so the claim's generality is untested against IL-23, IL-12/23, and JAK agents. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A multi-comparator active-comparator cohort scoring IBD incidence for IL-17i against each other advanced-therapy class with propensity adjustment.
Open question: Does IL-17 inhibitor use raise IBD risk relative to IL-23, IL-12/23, or JAK inhibitors, not just apremilast? Why it is still open: The corpus compares only apremilast [1][2] and etanercept [2]; the null etanercept result shows the signal is comparator-dependent.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 18 Sep 2026 · protocol v0.19